INTRODUCTION
Worldwide more than 220 000 men die annually of prostate cancer, usually as a result of metastases. 1 Today, androgen ablation (hormonal therapy) is the first-line therapy for metastatic prostate cancer, resulting in a transient reduction of symptoms and tumor progression until these cancers become androgenindependent and rapidly progressive. Androgen-independent prostate cancer is only moderately sensitive to chemotherapy.
The striking success of new targeted drugs raise the hope that prostate cancer patients might eventually also benefit from such an approach. 2 However, the few clinical trials in prostate cancer using drugs targeting epidermal growth factor receptor, 3, 4 vascular endothelial growth factor, 5 prostate stem cell antigen 6 and HER2 [7] [8] [9] were discouraging so far. Neuron-glia-related cell-adhesion molecule (Nr-CAM) is another potential membranebound target molecule for specific prostate cancer therapy. Nr-CAM belongs to the immunglobulin (Ig) superfamily. 10 Together with L1, CHL1 and neurofascin, it builds the L1 family of IgCAMs.
11 Nr-CAM acts as an adhesion molecule and has a role in axonal guidance and growth. 12 Accumulating data suggest that Nr-CAM has also relevance in non-neuronal tissues. It was suggested that Nr-CAM expression in endothelium may have a role in mediating capillary outgrowth. 13 Nr-CAM is also expressed in a variety of neoplastic tissues and cancer-derived cell lines, including pancreatic cancer, 14 melanoma, 15 colon carcinoma, 15 glioblastoma multiforme, 16 astrocytoma, 16 glioma 16 and papillary thyroid carcinoma. 17 For some cancer types, an association between Nr-CAM expression and unfavorable prognosis/ phenotype was suggested, including cerebral and thyroid cancers. 16, 17 Functional data also support a role of Nr-Cam in tumor biology. In melanoma cell lines, an association of high Nr-CAM expression with increased tumorigenicity was shown in one study. 15 The role of Nr-CAM in normal and neoplastic prostate epithelium has not been extensively studied. Normal prostate epithelium was described as a tissue with a relatively low expression level in one study. 16 A reduced expression of Nr-CAM has also been described in slow-growing prostate cancer in mice. 18 The aim of our study is to evaluate the prevalence of Nr-CAM expression in prostate cancer and to explore its association with phenotype and clinical disease course. The analysis of a preexisting tissue microarray (TMA) including more than 3000 prostate cancers with clinical follow-up data demonstrated that Nr-CAM expression is frequent in prostate cancer, and that high level of Nr-CAM expression is associated with favorable tumor phenotype and reduced risk of PSA recurrence. 1 
MATERIALS AND METHODS Patients
Radical prostatectomy specimens were available from 3261 patients, consecutively treated at the Department of Urology, University Medical Center Hamburg-Eppendorf between 1992 and 2005 (Table 1) . Follow-up data were available for 2891 patients, ranging from 0.03 to 219 months (mean, 72.1 months). None of the patients received neo-adjuvant or adjuvant therapy. Additional (salvage) therapy was only initiated after a biochemical relapse, the clinical endpoint of this study. In all patients, PSA values were measured quarterly in the first year, followed by biannual measurements in the second and annual measurements after the third year following surgery. Recurrence was defined as a postoperative PSA of 0.1 ng ml À 1 and rising. The first PSA values above or equal to 0.2 ng ml
were used to define the time of recurrence. Patients without evidence of tumor recurrence were censored at last follow-up. All prostatectomy specimens were analyzed according to a standard procedure. All prostates were completely paraffin-embedded, including whole-mount sections as previously described. 19 One 0.6-mm tissue core was punched out from the diagnostically relevant cancer area of each case and transferred in a TMA format as described. 20 The 3261 cores were distributed among seven TMA blocks each containing 129-522 tumor samples. Each TMA block also contained various control tissues, including normal prostate tissue and other normal tissues. The utilization of tissues and clinical data was approved by our local Ethical Committee.
Immunhistochemistry
Freshly cut TMA sections were stained in 1 day during a single experiment. High-temperature pretreatment of slides was done in an autoclave in citrate buffer, pH 9. Nr-CAM immunostaining was performed using a commercial polyclonal antibody (goat antihuman Nr-CAM antibody; AF2034, R & D Systems, Minneapolis, MN, USA). The specifity to the antibody was determined by the manufacturer. Normal pancreatic tissue was used as a positive control as previously described.
14 Lymphoid tissue was used as a negative control. The Envision system (DAKO, Glostrup, Denmark) was used to visualize the immunostaining. Only membranous staining was evaluated because cytoplasmatic staining-if present-was usually linked to a particularly strong membranous staining. The staining intensity (0, 1 þ , 2 þ and 3 þ ) and the fraction of positive tumor cells were recorded for each tissue spot. A final score was built from these two parameters according to the following: negative scores had staining intensity of 0, weak ones had a staining intensity of 1 þ in p70% of tumor cells or 2 þ in p30% of tumor cells; moderate had staining intensity of 1 þ in 470% of tumor cells, staining intensity of 2 þ in 430% and p70% of tumor cells or staining intensity of 3 þ in p30% of tumor cells and strong scores had staining intensity of 2 þ in 470% of tumor cells or staining intensity of 3 þ in 430% of tumor cells.
Statistics
Statistical calculations were performed using JMP statistical software (SAS Institute, Cary, NC, USA). Contingency tables were calculated with the w 2 test to analyze the relationship between categorical parameters. Survival curves were calculated by the Kaplan-Meier method and compared with the log-rank test.
RESULTS

Technical issues
A total of 2883 (88.4%) of tumor samples were interpretable in our TMA analysis. Reasons for non-informative cases (378 spots; 11.6%) included lack of tissue samples or absence of unequivocal cancer tissue in the TMA spot.
Immunohistochemistry Nr-CAM staining always showed strong membrane predominance in our tissues. Although some cytoplasmatic staining was sometimes seen, this was mostly associated with a much higher staining level on the membranes. Examples of Nr-CAM-positive and -negative cancers are shown in Figure 1a and b. Membranous Nr-CAM staining was seen in 1418 (49.2%) of 2883 analyzable cases. According to our predefined criteria, staining was considered weak in 778 (27.0%), moderate in 412 (14.3%) and strong in 228 (7.9%) cancers. Low or no expression of Nr-CAM was observed in benign prostate epithelium compared with many invasive cancers (Figure 1c and d) .
The relationship between Nr-CAM immunostaining and tumor phenotype is given in Table 2 . In general, positive Nr-CAM expression was associated with favorable tumor phenotype. Significant associations were found with pathological tumor stage (P ¼ 0.0015), Gleason grade (P ¼ 0.0003), nodal stage (P ¼ 0.0061), preoperative PSA (P ¼ 0.0138) and prolonged PSA recurrence-free survival (Po0.0001, Figure 2a ). This held true if all tumors were analyzed but also for the subgroup of Gleason p3 þ 4 cancer (Figure 2b) . The association was lost in high-grade (Gleason X4 þ 3) cancers (Figure 2c ). The massive association between Gleason grade and PSA recurrence is also given as a reference for the quality of clinical follow-up data (Figure 2d ).
DISCUSSION
The results of this study show that many prostate cancers show elevated Nr-CAM expression as compared with normal epithelium and that such high Nr-CAM expression is associated with favorable tumor phenotype and prolonged PSA recurrence-free survival in prostate cancer patients. Our immunohistochemical comparison of normal prostate epithelium and prostate cancer demonstrates that almost 50% of prostate cancers upregulate membranous Nr-CAM protein during tumor development and/or progression. It is conceivable that high availability of a cell-adhesion molecule such as Nr-CAM goes along with decreased capabilities of cells for invasion, Nr-CAM expression in prostate cancer MC Tsourlakis et al migration and metastasis. However, the observation of a celladhesion molecule being upregulated in cancer as compared with normal prostate epithelium and at the same time conferring a favorable prognosis to affected tumors is counterintuitive. There are at least two different conceptual explanations for such a scenario. First, it is possible that Nr-CAM may represent a protective mechanism in cells with a cancer-prone metabolic alteration. In such a case, Nr-CAM protein expression would be activated in case of cellular alterations that are typically associated with cancer. Poorly differentiated prostate cancers may be more likely to loose the functionality of such a mechanism, which could then contribute to the more aggressive behavior of these neoplasms. Alternatively, our Nr-CAM data are also consistent with a complete lack of a specific functional role of Nr-CAM overexpression in prostate cancer biology. The unexpected overexpression of a cell-adhesion molecule in some prostate cancer 'with the purpose of making the cancer more benign' may just represent a simple 'bystander effect'. It is well known from expression screening studies that hundreds or thousands of genes are dysregulated in cancer cells. [21] [22] [23] Accordingly, high levels of Nr-CAM expression might represent an unspecific event in a clinically less-aggressive molecular prostate cancer subgroup that has no direct effects on a cells cancer properties. Data from other groups on Nr-CAM expression in prostate cancer are currently lacking, but similar observations have been described for pancreatic carcinoma. 14 Dhodapkar et al 14 found increased Nr-CAM expression in areas of well and moderately differentiated carcinoma (54%), while most poorly differentiated lesions did not exhibit Nr-CAM surface expression. In the same study, a lack of Nr-CAM expression is described in three of five patients with poorly differentiated tumors who presented with lymph node metastasis not only in the poorly differentiated but also in the well-differentiated areas. 14 However, other authors reported a worse tumor phenotype and unfavorable clinical outcome to be associated with high Nr-CAM protein levels in several other tumor entities. 16, 17, 24 For example, Sehgal et al. 16 found significantly more Nr-CAM expression in astrocytoma IV and glioblastoma cell lines as compared with cell lines from astrocytoma III, and concluded that overexpression of Nr-CAM is a late event in this tumor entity. Gorka et al. 17 found higher amounts of Nr-CAM mRNA in pT3/pT4N1 papillary thyroid carcinomas than in low stage tumors, but these differences were not statistically significant. In the same study, the authors could not find any association between Nr-CAM expression and regional lymph node metastasis. Overexpression of Nr-CAM in ependymomas was associated with poor outcome. 24 These controversial data argue for different mechanisms of action for Nr-CAM in different cell types/tissues. It is possible that these variations may be owing to variable interactions with other molecules as suggested by Gibson et al. 25 Denburg et al 26 suggest that the existence of multiple conformation states of this celladhesion molecule might be the reason for its different functions.
In this study, a small but significant prognostic effect of Nr-CAM expression was demonstrated using a TMA approach. This observation further corroborates our approach of utilizing just one 0.6 mm tissue spot per cancer in prostate cancer TMA studies to identify prognostic molecular features. While it is possible or even likely that our approach of analyzing one TMA spot per cancer will have missed several cancers with heterogeneous Nr-CAM positivity, it appears unlikely that a better identification of a few additional Nr-CAM-positive cancers would have lead to a markedly different outcome of our analysis. The TMA used for this project was earlier successfully used to identify a prognostic relevance of multiple biomarkers on the protein and DNA level. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Some investigators had proposed that multiple tissue spots per prostate cancer would be advantageous for the identification of clinically relevant biomarkers. [37] [38] [39] [40] [41] [42] [43] [44] However, we recently showed for several biomarkers that the number of cores per tumor has no or little impact on study results in the case of large-scale TMAs. 45 The abundant presence of Nr-CAM in prostate cancer epithelium makes Nr-CAM a potential target of therapy. This notion is supported by experiments by Sehgal et al. 46 showing that antisense Nr-CAM causes a reduction in the native Nr-CAM expression and proliferation of Nr-CAM-positive glioblastoma cells in mice.
In summary, our data show that Nr-CAM is abundantly expressed in prostate cancer. High levels of Nr-CAM expression are linked to favorable prostate cancer phenotype and characterize a subset of tumors with a prolonged PSA recurrence-free interval. It can be hoped that biomarkers such as Nr-CAM expression levels in combination with other molecular features will substantially improve the individual prediction of prostate cancer aggressiveness.
